Dialysis giant NephroPlus, the largest service provider in Asia and the fifth-largest globally by treatments performed in FY25, will open its Initial Public Offering (IPO) on Wednesday, December 10, closing on Friday, December 12. The company has set the price band at ₹438–₹460 per equity share, with a ₹41 discount offered to eligible employees.
The public issue will include a fresh issue of ₹353.4 crore and an offer for sale of 1,12,53,102 shares by selling shareholders.
NephroPlus intends to deploy ₹129.1 crore of the proceeds for opening new dialysis centres across India, while ₹136 crore has been earmarked for pre-payment or scheduled repayment of certain borrowings.
Established in 2009, the company is India’s largest organised dialysis network, with facilities spanning 288 cities in 21 states and 4 Union Territories. It operates a global network of 519 clinics, including 51 centres in the Philippines, Uzbekistan and Nepal. Its 165-bedded clinic in Tashkent stands as the largest dialysis clinic worldwide.
The company’s service offerings include haemodialysis, home haemodialysis, hemodiafiltration, holiday dialysis, dialysis on call and dialysis on wheels.
India’s dialysis services industry, valued at USD 818 million in FY24, is projected to grow to USD 1,979 million by 2029.
